GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CB Scientific Inc (OTCPK:CBSC) » Definitions » Loans Receivable

CB Scientific (CB Scientific) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is CB Scientific Loans Receivable?

CB Scientific's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


CB Scientific Loans Receivable Historical Data

The historical data trend for CB Scientific's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CB Scientific Loans Receivable Chart

CB Scientific Annual Data
Trend Mar21 Mar22 Mar23
Loans Receivable
- - -

CB Scientific Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CB Scientific Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


CB Scientific Loans Receivable Related Terms

Thank you for viewing the detailed overview of CB Scientific's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


CB Scientific (CB Scientific) Business Description

Traded in Other Exchanges
N/A
Address
10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
CB Scientific Inc through its U.S. and international subsidiaries provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.